BSE Live
Nov 14, 16:01Prev. Close
1234.55
Open Price
1241.30
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 14, 15:58Prev. Close
1234.90
Open Price
1235.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Dr Reddys Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 10,010.40 | 9,728.80 | 8,316.50 | 6,708.30 | 5,284.70 | |
| Less: Excise/Sevice Tax/Other Levies | 82.90 | 82.00 | 71.80 | 40.50 | 35.60 | |
| Revenue From Operations [Net] | 9,927.50 | 9,646.80 | 8,244.70 | 6,667.80 | 5,249.10 | |
| Total Operating Revenues | 10,011.00 | 9,728.00 | 8,434.00 | 6,739.70 | 5,304.50 | |
| Other Income | 222.80 | 151.50 | 141.70 | 81.80 | 119.60 | |
| Total Revenue | 10,233.80 | 9,879.50 | 8,575.70 | 6,821.50 | 5,424.10 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 2,248.40 | 2,191.80 | 2,277.30 | 1,738.60 | 1,335.10 | |
| Purchase Of Stock-In Trade | 526.10 | 469.00 | 393.10 | 307.60 | 331.00 | |
| Operating And Direct Expenses | 92.40 | 78.50 | 59.20 | 50.50 | 27.60 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -28.90 | -114.40 | -100.60 | -104.80 | -79.00 | |
| Employee Benefit Expenses | 1,490.90 | 1,184.90 | 1,138.10 | 866.10 | 727.40 | |
| Finance Costs | 63.80 | 78.30 | 61.40 | 63.60 | 5.30 | |
| Depreciation And Amortisation Expenses | 490.20 | 380.50 | 312.80 | 301.10 | 247.90 | |
| Other Expenses | 3,291.00 | 3,132.00 | 2,658.90 | 2,147.10 | 1,721.20 | |
| Total Expenses | 8,173.90 | 7,425.10 | 6,822.50 | 5,562.30 | 4,372.20 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 2,059.90 | 2,454.40 | 1,753.20 | 1,259.20 | 1,051.90 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 2,059.90 | 2,454.40 | 1,753.20 | 1,259.20 | 1,051.90 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 376.70 | 490.10 | 414.00 | 344.40 | 215.90 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | -83.10 | 83.10 | |
| Deferred Tax | 3.80 | 31.50 | 73.70 | -80.70 | 25.70 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 380.50 | 521.60 | 487.70 | 346.80 | 158.50 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 1,679.40 | 1,932.80 | 1,265.50 | 912.40 | 893.40 | |
| Profit/Loss From Continuing Operations | 1,679.40 | 1,932.80 | 1,265.50 | 912.40 | 893.40 | |
| Profit/Loss For The Period | 1,679.40 | 1,932.80 | 1,265.50 | 912.40 | 893.40 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 99.00 | 114.00 | 75.00 | 53.83 | 52.82 | |
| Diluted EPS (Rs.) | 98.00 | 113.00 | 74.00 | 53.56 | 52.51 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 867.70 | 811.90 | 688.50 | 470.40 | 692.70 | |
| Indigenous Raw Materials | 1,380.70 | 1,379.80 | 1,588.80 | 1,268.30 | 642.40 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 81.10 | 6.40 | 8.30 | 4.70 | 5.00 | |
| Indigenous Stores And Spares | 294.40 | 88.20 | 93.20 | 71.90 | 78.40 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 340.80 | 306.20 | 254.80 | 233.10 | 190.40 | |
| Tax On Dividend | 69.40 | 52.00 | 43.30 | 37.80 | 115.20 | |
| Equity Dividend Rate (%) | 400.00 | 360.00 | 300.00 | 275.00 | 225.00 |
11.11.2025
30.10.2025
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz